43.65
price up icon0.92%   0.40
pre-market  プレマーケット:  42.49   -1.16   -2.66%
loading
前日終値:
$43.25
開ける:
$42.82
24時間の取引高:
666.09K
Relative Volume:
0.54
時価総額:
$5.20B
収益:
$10.60M
当期純損益:
$-252.45M
株価収益率:
-14.08
EPS:
-3.1
ネットキャッシュフロー:
$-158.91M
1週間 パフォーマンス:
-16.86%
1か月 パフォーマンス:
-13.48%
6か月 パフォーマンス:
+49.28%
1年 パフォーマンス:
+631.16%
1日の値動き範囲:
Value
$42.20
$44.64
1週間の範囲:
Value
$39.50
$54.24
52週間の値動き範囲:
Value
$5.68
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
名前
Avidity Biosciences Inc
Name
セクター
Healthcare (1193)
Name
電話
858-401-7900
Name
住所
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
職員
253
Name
Twitter
Name
次回の収益日
2024-12-07
Name
最新のSEC提出書
Name
RNA's Discussions on Twitter

RNA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
RNA 43.65 5.20B 10.60M -252.45M -158.91M -3.10
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-09-24 開始されました Goldman Buy
2024-08-28 開始されました Barclays Overweight
2024-05-03 開始されました BofA Securities Buy
2024-03-14 開始されました Cantor Fitzgerald Overweight
2023-05-22 アップグレード Evercore ISI In-line → Outperform
2023-03-31 ダウングレード Evercore ISI Outperform → In-line
2022-07-20 開始されました Chardan Capital Markets Buy
2022-07-12 開始されました Raymond James Strong Buy
2021-09-07 開始されました Evercore ISI Outperform
2021-06-17 開始されました Needham Buy
2021-04-26 再開されました Credit Suisse Outperform
2020-07-07 開始されました Cowen Outperform
2020-07-07 開始されました Credit Suisse Outperform
2020-07-07 開始されました SVB Leerink Outperform
2020-07-07 開始されました Wells Fargo Overweight
すべてを表示

Avidity Biosciences Inc (RNA) 最新ニュース

pulisher
Nov 20, 2024

Avidity Biosciences director Arthur Levin sells $139,972 in stock By Investing.com - Investing.com South Africa

Nov 20, 2024
pulisher
Nov 20, 2024

Avidity Biosciences' chief HR officer Teresa McCarthy sells $1.03m in stock - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Mutual of America Capital Management LLC Cuts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Research Analysts Set Expectations for RNA FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Los Angeles Capital Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

12,319 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Assetmark Inc. - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Avidity Biosciences unveils new cardiology development candidates - BioWorld Online

Nov 14, 2024
pulisher
Nov 14, 2024

RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - Yahoo! Voices

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 - Quantisnow

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year HighShould You Buy? - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire

Nov 13, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - PR Newswire

Nov 12, 2024
pulisher
Nov 09, 2024

Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance

Nov 09, 2024
pulisher
Nov 09, 2024

431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences CFO sells $4.8 million in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences CFO sells $4.8 million in stock By Investing.com - Investing.com Canada

Nov 09, 2024
pulisher
Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition in Avidi - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - BioSpace

Nov 08, 2024
pulisher
Nov 08, 2024

Avidity Biosciences Reports Strong Q3 Progress and Outlook - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Avidity Bio's DMD Drug Shows 25% Dystrophin Boost; Reports $1.6B Cash Position | RNA Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 04, 2024

Avidity Biosciences (NASDAQ:RNA) Trading Up 6.5%What's Next? - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Vanguard Group Inc's Strategic Acquisition in Avidity Biosciences Inc - GuruFocus.com

Nov 04, 2024
pulisher
Nov 02, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused o - GuruFocus.com

Nov 02, 2024
pulisher
Oct 31, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 – Company AnnouncementFT.com - Financial Times

Oct 31, 2024
pulisher
Oct 31, 2024

Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Avidity Biosciences advances FSHD therapy trial By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Avidity Biosciences target held at $59 by Goldman Sachs - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Chardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00 - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Faciosca - StreetInsider.com

Oct 30, 2024

Avidity Biosciences Inc (RNA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Avidity Biosciences Inc (RNA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
McCarthy Teresa
Chief Human Resources Officer
Nov 18 '24
Sale
41.14
25,000
1,028,520
94,018
LEVIN ARTHUR A
Director
Nov 19 '24
Option Exercise
1.24
3,323
4,121
18,153
LEVIN ARTHUR A
Director
Nov 19 '24
Sale
42.12
3,323
139,973
14,830
MacLean Michael F
Chief Financial Officer
Nov 06 '24
Option Exercise
8.43
79,057
666,064
159,275
MacLean Michael F
Chief Financial Officer
Nov 06 '24
Sale
45.56
106,319
4,843,979
94,093
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
大文字化:     |  ボリューム (24 時間):